Details

Autor(en) / Beteiligte

• Zhang, F.-R
• Liu, H
• Irwanto, A
• Fu, X.-A
• Li, Y
• Yu, G.-Q
• Yu, Y.-X
• Chen, M.-F
• Low, H.-Q
• Li, J.-H
• Bao, F.-F
• Foo, J.-N
• Bei, J.-X
• Jia, X.-M
• Liu, J
• Liany, H
• Wang, N
• Niu, G.-Y
• Wang, Z.-Z
• Shi, B.-Q
• Tian, H.-Q
• Liu, H.-X
• Ma, S.-S
• Zhou, Y
• You, J.-B
• Yang, Q
• Wang, C
• Chu, T.-S
• Liu, D.-C
• Yu, X.-L
• Sun, Y.-H
• Ning, Y
• Wei, Z.-H
• Chen, S.-L
• Chen, X.-C
• Zhang, Z.-X
• Liu, Y.-X
• Pulit, S.L
• Wu, W.-B
• Zheng, Z.-Y
• Yang, R.-D
• Long, H
• Liu, Z.-S
• Wang, J.-Q
• Li, M
• Zhang, L.-H
• Wang, H
• Wang, L.-M
• Xiao, P
• Li, J.-L
• Huang, Z.-M
• Huang, J.-X
• Li, Z
• Xiong, L
• Yang, J
• Wang, X.-D
• Yu, D.-B
• Lu, X.-M
• Zhou, G.-Z
• Yan, L.-B
• Shen, J.-P
• Zhang, G.-C
• Zeng, Y.-X
• de Bakker, P.I.W
• Chen, S.-M
• Liu, J.-J

Titel

HLA-B13:01 and the Dapsone Hypersensitivity Syndrome

Ist Teil von

• The New England journal of medicine, 2013-10, Vol.369 (17), p.1620-1628

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• Dapsone is an important medication for the treatment of leprosy, but a life-threatening drug hypersensitivity syndrome develops in some patients. In this report from China, an HLA-B locus is identified as a strong genetic risk factor for the syndrome. Dapsone (4-4′-sulfonyldianiline), which was first synthesized in 1908, 1 is both an antibiotic and an antiinflammatory agent. Dapsone alone or in combination with other drugs has been used for the prevention and treatment of infectious diseases (e.g., leprosy, malaria, and actinomycetoma, as well as Pneumocystis jirovecii pneumonia in persons with human immunodeficiency virus [HIV] infection) and chronic inflammatory diseases characterized by the infiltration of neutrophils or eosinophils (e.g., dermatitis herpetiformis, linear IgA dermatosis, subcorneal pustular dermatosis, and erythema elevatum diutinum). 2 , 3 About 0.5 to 3.6% of persons treated with dapsone have a drug hypersensitivity syndrome, 3 – 5 which was first described by . . .